Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer’s Disease Clinical Trials: Potential for Confounding by Indication

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

(2017) John T O’Brien et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A phase 3 trial of IV immunoglobulin for Alzheimer disease

(2017) Norman R. Relkin et al.   NEUROLOGY

Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study

(2017) S. Bakchine et al.   JOURNAL OF ALZHEIMERS DISEASE

Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials

(2016) Ronald G. Thomas et al.   Alzheimers & Dementia

Confounding by Indication in Clinical Research

(2016) Demetrios N. Kyriacou et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

(2015) R. Schmidt et al.   EUROPEAN JOURNAL OF NEUROLOGY

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

(2015) R. Scott Turner et al.   NEUROLOGY

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

(2015) Alireza Atri et al.   Alzheimers Research & Therapy

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

(2013) George T. Grossberg et al.   CNS DRUGS

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

(2012) Serge Gauthier et al.   Alzheimers & Dementia

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

(2012) Lucy E Farrimond et al.   BMJ Open

Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease

(2011) Lon S. Schneider   ARCHIVES OF NEUROLOGY

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

(2011) M. Sano et al.   NEUROLOGY

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

(2010) Joseph F. Quinn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

(2008) Anton Porsteinsson et al.   Current Alzheimer Research

High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease

(2008) Paul S. Aisen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION